02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
18:32 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Biogen's aducanumab shows continued improvements through 48 weeks in Phase Ib extension for Alzheimer’s

Biogen Inc. (NASDAQ:BIIB) reported additional data from the long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels through 48...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
22:51 , Apr 6, 2018 |  BioCentury  |  Finance

Picking season

  Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke...
20:44 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Biogen updates Phase III AD studies

EVP and CMO Alfred Sandrock from Biogen Inc. (NASDAQ:BIIB) said the company will enroll a total of an additional 510 patients in the Phase III ENGAGE and EMERGE trials of aducanumab (BIIB037) to treat early...
00:38 , Feb 15, 2018 |  BC Extra  |  Clinical News

Biogen slips on Phase III AD studies

Biogen Inc. (NASDAQ:BIIB) lost $20.91 to $296.08 on Wednesday after EVP and CMO Alfred Sandrock said the company will enroll a total of an additional 510 patients in the Phase III ENGAGE and EMERGE trials...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
17:04 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Eisai, Biogen continuing AD trial of BAN2401 despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to...